Abstract：Objective: To investigate the correlation between the level of plasma MicroRNA-17-5p and microRNA-20 and the severity and prognosis of pulmonary arterial hypertension (PAH). Methods: A microarray screen was performed on total plasma RNA from 112 patients with PAH and 100 healthy control subjects Quantitative polymerase chain reaction commend increased microRNA-17-5p and microRNA-20a concentrations and was then used to measure microRNA-17-5p and microRNA-20a levels in cohort of patients with PAH's circulating microvesicles and blood cells. Results: Fifty-eight miRNAs showed differences in plasma concentration. MicroRNA-17-5p and microRNA-20a are the largest up-regulation in PAH. Receiver-operator-characteristic analysis showed both raw and normalized plasma microRNA-17-5p and microRNA-20a levels correlated with 2-year survival in patients with PAH. Cox regression analysis confirmed that miRNA-17-5p and miRNA-20a levels were important predictors of PAH survival. Age, baseline cardiac index, World Health Organization functional class, 6-minute walk distance, disease duration, and red cell distribution width also predicted survival. Entering these covariates in a multivariable model veried plasma microRNA-17-5p and microRNA-20a levels as independent predictoras of survival in PAH. Conclusion: Increased circulating microRNA-17-5p and microRNA-20a levels are associated with poor survival in PAH.
张岩, 王聪霞, 李永勤, 张春艳, 胡艳超, 李满祥. 血浆MicroRNA-17-5p和microRNA-20水平与肺动脉高压预后的相关性研究[J]. 河北医学, 2017, 23(8): 1236-1241.
ZHANG Yan, WANG Congxia, LI Yongqin, et al. Correlation between Plasma Levels of MicroRNA-17-5p and microRNA-20 and Prognosis of Pulmonary Arterial Hypertension. 河北医学, 2017, 23(8): 1236-1241.
[1] Chandra SM, Razavi H, Kim J,et al . Disruption of the Apelin-APJ system worsens hypoxia-induced pulmonary hypertension[J].Arterioscl Throm Vas, 2011, 31(5): 814~821. [2] Kim J. Apelin-APJ Signaling: a potential therapeutic target for pulmonary arterial hypertension[J].Mol Cells, 2014,37(5): 196~201. [3] Courboulin A, Paulin R, Giguere NJ, et al. Role for miR-204 in human pulmonary arterial hypertension[J].Exp Med, 2011,211(9):535~548. [4] Brock M, Trenkmann M, Gay RE, et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type Ⅱ through a novel STAT3-microRNA cluster 17/92 pathway[J].Circ Res, 2009,104(10):1184~1191. [5] Mclaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association[J].Circulation, 2009,119(6):2250~2294. [6] Davis BN, Hilyard AC, Lagna G, et al. SMAD proteins control DROSHA-mediated microRNA maturation[J].Nature, 2008,454(6):56~61. [7] Caruso P, Maclean MR, Khanin R, et al. Dynamic changes in lung microRNA process during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline[J].Arterioscler Thromb Vasc Biol ,2010,30(7):716~723. [8] Parikh VN, Jin RC, Rabello S, et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach[J].Circulation, 2012, 125(8):1520~1532. [9] Hogan BL. Bone morphogenetic proteins: multi-functional regulators of vertebrate development[J].Genes Dev, 2015,10(7): 1580~1594. [10] Machado RD, Aldred M A, James V, et al . Mutations of the TGF-beta type Ⅱ receptor BMPR2 in pulmonary arterial hypertension[J].Hum Mutat, 2016, 27(8):121~132. [11] Brock M, Trenkmann M, Gay R E,et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type Ⅱ through a novel STAT3-microRNA cluster 17/92 pathway[J].Circ Res, 2015, 104(8):1184~1191. [12] Pullamsetti SS, Doebele C, Fischer A, et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension[J].Am Respir Crit Care Med, 2013,185(7): 409~419. [13] Brock M, Samillan VJ, Trenkmann M, et al. Antagomir directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension[J].Eur Heart, 2012, 12(4):60~70. [14] Zaidi SH, You XM, Ciura S, et al. Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension[J].Circulation ,2002,105(9):516~521. [15] Takahashi H, Goto N, Kojima Y, et al. Down regulation of type Ⅱ bone morphogenetic protein receptor in hypoxic pulmonary hypertension[J].Am Physiol Lung Cell Mol Physiol, 2006,290(8):450~458.
2017, Vol. 23 
冀公网安备13080202000677号